Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tremelimumab
- Development stage
- Approved
- Lead developer
- AstraZeneca
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Tremelimumab is a fully human IgG2 monoclonal antibody immune checkpoint inhibitor that targets cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), a negative regulator of T-cell activation. By binding to CTLA-4 and blocking its interaction with ligands CD80 and CD86, tremelimumab enhances T-cell activation and proliferation, resulting in increased antitumor immune activity. It is primarily used in combination with durvalumab for the treatment of unresectable hepatocellular carcinoma (HCC) and metastatic non-small cell lung cancer (NSCLC) without EGFR or ALK mutations. Tremelimumab was developed as an immunotherapy for cancer by AstraZeneca/MedImmune.
- Brand names
- Imjudo
- Other names
- tremelimumab-actl
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on tremelimumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tremelimumab.